Regeneron Pharmaceuticals Return On Asset Trend

<div class='logoBackup' style='background:#0D8ECF;color: white;font-size:4em;padding-top: 15px;;'>RE</div>
REGN -- USA Stock  

Fiscal Year End: February 5, 2020  

Check Regeneron Pharmaceuticals fundamental indicators over time to gain insight into the company future performance. Apply historical fundamental analysis to find patters among financial statement drivers such as Direct Expenses of 298 M, Consolidated Income of 476.6 M or Cost of Revenue of 175.6 M, as well as many exotic indicators such as Interest Coverage of 72.3105, Long Term Debt to Equity of 0.2017 or Calculated Tax Rate of 10.5632. This can be a perfect complement to check Regeneron Pharmaceuticals Valuation or Volatility. It can also complement various Regeneron Pharmaceuticals Technical models. Additionally take a look at analysis of Regeneron Pharmaceuticals Correlation with competitors.

Regeneron Pharmaceuticals Return On Asset Marginal Breakdown

Showing smoothed Return on Average Assets of Regeneron Pharmaceuticals with missing and latest data points interpolated. Return on assets measures how profitable a company is [NetIncCmn] relative to its total assets [AssetsAvg].


          10 Years Trend
 Return on Average Assets 

Regeneron Pharmaceuticals Regression Statistics

Arithmetic Mean 11.21
Coefficient Of Variation 155.34
Mean Deviation 12.64
Median 15.23
Standard Deviation 17.41
Sample Variance 303.11
Range 62.46
R Value 0.54
Mean Square Error 235.61
R Squared 0.29
Significance 0.07
Slope 2.62
Total Sum of Squares 3,334

Regeneron Pharmaceuticals Return On Asset Over Time

2018  23.85 
2019  21.46 
2020  16.35 

Other Fundumenentals of Regeneron Pharmaceuticals